CODX
Earnings, but make it a business plan
Co-Diagnostics dropped its second-quarter 2026 results on Aug. 13, but the headline here is less “how did the quarter go?” and more “here’s everything we’re trying to turn on at once.” The company leaned hard into commercialization, regulatory momentum, and manufacturing scale-up — basically the biotech equivalent of trying to graduate, get a job, and move apartments all in the same week.
The Saudi manufacturing plot twist
One of the bigger nuggets: the company advanced its manufacturing strategy in Saudi Arabia after getting approval for a manufacturing facility industrial site and signing a lease in Sudair Industrial City. That matters because localized production can make future commercialization across the Middle East and North Africa a lot smoother — assuming the rollout actually keeps moving and doesn’t get stuck in the usual “great slide deck, now what?” phase.
Going global, one conference booth at a time
Co-Dx also said it expanded commercial outreach through a European trade mission with the Utah Governor’s Office and World Trade Center Utah, while showing off its Co-Dx PCR platform and CE-IVD solutions at ESCMID Global 2026. Translation: it’s trying to get in front of buyers, distributors, and strategic partners instead of waiting for the phone to ring. It also presented its PCR tuberculosis platform at the Stop TB Partnership Summit in Washington, D.C., which keeps the company in front of the clinical and public-health crowd.
Why investors should keep watching
For a small diagnostics name like CODX, this is the classic prove-it story. The market usually gives a polite golf clap for “we’re working on commercialization,” but it wants evidence — regulatory progress, manufacturing readiness, and actual customer traction. Big picture: if Co-Diagnostics can keep stacking these operational wins, the story starts looking less like a science fair project and more like a real platform business.